Aggiornamento 1 di 1UltimoGiorno 1
Twenty-Seven Dead, No FDA Approval, and a Presidential Pen
Trump's April executive order fast-tracks ibogaine, a Schedule I psychedelic with documented cardiac risk, while Americans keep dying at unregulated clinics abroad.
Cosa sapevamo all'inizio
- At least 27 Americans have died taking ibogaine at unregulated clinics abroad.
- Trump signed the executive order on April 18, 2026, directing the FDA to expedite ibogaine review.
- Ibogaine remains a DEA Schedule I controlled substance with no FDA approval.
- Ibogaine can prolong the heart's QT interval, with potentially fatal consequences.
Allora ancora aperto
- The full death toll at foreign clinics, including non-American patients, is not publicly tracked.
- How the FDA will interpret "expedite" — whether it fast-tracks a specific application or reopens the research pathway — has not been disclosed.
- Whether Texas's state-funded trials will produce randomized data sufficient for an FDA submission.
Cosa avevamo detto di seguire
- Whether the FDA names a specific ibogaine application for priority review before the end of 2026.
- Whether any new deaths at foreign clinics are reported and attributed to specific protocols.
- Whether congressional veterans' affairs committees hold hearings on the cardiac-risk evidence.
